IQVIA, a provider of clinical research services and healthcare intelligence, has entered into a strategic collaboration with Flagship Pioneering to accelerate the development of early-stage life sciences companies. The partnership
Rob Kotchie, President of Real World Solutions at IQVIA, stated, “Working with Flagship Pioneering to foster the development of emerging biopharma companies that will advance the development of life-saving therapies fits squarely within IQVIA’s mission to accelerate innovations for a healthier world and bring better treatments to patients faster.”
The collaboration will focus on three key areas: drug development strategy and analytics, clinical development execution, and asset valuation and due diligence. Flagship Pioneering, which has originated more than 100 scientific ventures with over $60 billion in aggregate value, views the alliance as a way to strengthen the capabilities of its platform companies. “By using IQVIA’s robust data infrastructure and analytics capabilities alongside Flagship’s bioplatforms, this collaboration is poised to positively impact the ability of our companies to accelerate their platform capabilities and drive value creation for life sciences,” said David Khougazian, Executive Partner at Flagship Pioneering.